Endocrinology News

U.S. News & World Report announced its 2024-2025 Best Hospitals rankings Tuesday.

GLP-1 receptor agonist use in diabetes and obesity has soared, and indications are now expanding into liver diseases, specifically metabolic dysfunction-associated steatohepatitis. However, the jury is still out on its benefits.

A new drug application for sotagliflozin as an adjunct to insulin therapy for adults with type 1 diabetes and chronic kidney disease has been resubmitted to the FDA, according to a press release.

From 2005 to 2019 in Canada, type 1, type 2 and gestational diabetes prevalence in pregnancy steadily increased and is expected to continue to rise as more women with overweight conceive, researchers reported.

Fetal growth rate is higher for women with gestational diabetes in the third trimester, and that accelerated growth rate may contribute to an increased likelihood for overweight among children, according to study data from Denmark.

The Mayo Clinic in Rochester, Minnesota, has repeated as the No. 1 hospital in the U.S. for diabetes and endocrinology, according to the U.S. News & World Report’s 2024-2025 Best Hospitals rankings.

Children with presymptomatic type 1 diabetes progressed more quickly to type 1 diabetes after having COVID-19, according to a research letter published in JAMA.

Metabolic dysfunction-associated steatotic liver disease affects more than one-third of the world’s population and is associated with significant clinical and economic burden, as well as impairment of health-related quality of life.

To put it simply, diabetes and steatotic liver disease are joined at the hip. They are part of the same biological process that involves multiple organs, connected by the concept of metabolic flexibility — or lack thereof.

Metabolic dysfunction-associated steatohepatitis is significantly more common in patients with type 2 diabetes, and most patients with MASH — formerly known as NASH — experience metabolic abnormalities, including obesity.